DKK1 as a novel target for myeloma immunotherapy
نویسندگان
چکیده
منابع مشابه
DKK1 as a novel target for myeloma immunotherapy
Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.
متن کاملEvaluation of CD38 as Target for Immunotherapy in Multiple Myeloma
We have read with interest the report of Goldmacher et al.’ They describe the construction of an anti-CD38 imunotoxin (IT) by conjugating CD38 monoclonal antibody (MoAb) HB7 to blocked ricin. The resulting IT shows potent killing of plasma cell lines, whereas only low toxicity is observed for hematopoietic precursor cells (HPC). Therefore, they conclude that this HB7-blocked ricin may have clin...
متن کاملEvaluation of CD38 as target for immunotherapy in multiple myeloma.
We have read with interest the report of Goldmacher et al.’ They describe the construction of an anti-CD38 imunotoxin (IT) by conjugating CD38 monoclonal antibody (MoAb) HB7 to blocked ricin. The resulting IT shows potent killing of plasma cell lines, whereas only low toxicity is observed for hematopoietic precursor cells (HPC). Therefore, they conclude that this HB7-blocked ricin may have clin...
متن کاملCytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme
Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has remained marginal and GBM is still universally fatal with short survival times after initial diagnosis. Much research is focused on finding new therapeutics for GBM and immune-based approaches have shown great promise. The detection of cytomegalovirus (CMV) antigens in malignant cells has suggested that tre...
متن کاملNew Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoImmunology
سال: 2012
ISSN: 2162-402X
DOI: 10.4161/onci.19655